Foracort: Uses, Dosage & Side Effects

What Is Foracort and What Is It Used For?

Foracort belongs to a class of medications known as combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) therapies. These products combine two complementary pharmacological agents in a single inhaler device, simplifying treatment and improving adherence in patients with chronic airway diseases. The two active ingredients in Foracort – budesonide and formoterol fumarate dihydrate – work through distinct but complementary mechanisms to address both the underlying inflammation and the bronchoconstriction that characterize asthma and COPD.

Budesonide is a synthetic glucocorticoid with potent local anti-inflammatory activity in the lungs. When inhaled, it acts on multiple cell types within the airways, including epithelial cells, macrophages, eosinophils, mast cells, and T lymphocytes. Budesonide suppresses the production of pro-inflammatory cytokines (such as interleukin-4, interleukin-5, and interleukin-13), chemokines, and adhesion molecules that are central to the chronic inflammatory cascade in asthma. It also reduces airway hyperresponsiveness, mucus hypersecretion, and vascular permeability. By targeting the underlying inflammatory process, budesonide helps to prevent asthma exacerbations, reduce symptoms, and preserve lung function over time. Importantly, the topical delivery of budesonide to the lungs via inhalation allows for effective local concentrations while minimizing systemic exposure and the associated side effects of oral corticosteroids.

Formoterol fumarate dihydrate is a selective long-acting beta-2 adrenergic receptor agonist (LABA) with a rapid onset of action. When inhaled, formoterol activates beta-2 adrenergic receptors on airway smooth muscle cells, triggering an intracellular signaling cascade involving the enzyme adenylyl cyclase and the second messenger cyclic adenosine monophosphate (cAMP). The increase in intracellular cAMP causes relaxation of airway smooth muscle, resulting in bronchodilation. Unlike some other LABAs, formoterol has the advantage of a rapid onset of action (within 1–3 minutes), combined with a long duration of effect lasting at least 12 hours. This unique pharmacological profile makes formoterol particularly well suited for combination with inhaled corticosteroids, as it provides both prompt symptom relief and sustained bronchodilation throughout the dosing interval.

The rationale for combining an ICS with a LABA in a single inhaler is well established in international respiratory medicine guidelines. The Global Initiative for Asthma (GINA) recommends ICS/LABA combinations as the preferred controller therapy for patients with moderate-to-severe persistent asthma (GINA Steps 3–5). Clinical trials have consistently demonstrated that the combination of budesonide and formoterol provides superior asthma control compared with either agent alone or with higher doses of inhaled corticosteroids. The combination approach reduces exacerbation rates, improves lung function, decreases symptom burden, and allows for lower overall corticosteroid exposure.

In COPD, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends ICS/LABA combinations for patients in group E (those with frequent exacerbations and elevated blood eosinophil counts). The combination of budesonide and formoterol has been shown to reduce the rate of moderate and severe COPD exacerbations, improve quality of life as measured by validated instruments such as the St George’s Respiratory Questionnaire, and improve pre-dose forced expiratory volume in one second (FEV1) compared with formoterol alone in patients with moderate-to-severe COPD.

What Should You Know Before Taking Foracort?

Contraindications

Foracort is contraindicated in patients with known hypersensitivity (allergy) to budesonide, formoterol fumarate dihydrate, or any of the excipients in the formulation. While serious allergic reactions to inhaled budesonide/formoterol are rare, cases of urticaria, angioedema, rash, and bronchospasm have been reported. If you experience any signs of a severe allergic reaction, discontinue use immediately and seek medical attention.

Foracort should not be used as a primary treatment for acute asthma attacks or status asthmaticus, where intensive therapeutic measures and supervision are required. It is a maintenance medication designed for regular, ongoing use, not for the acute relief of sudden breathlessness. Patients should always have access to a short-acting inhaled beta-2 agonist (such as salbutamol) for the treatment of acute symptoms, unless they are on a MART regimen as directed by their physician.

Warnings and Precautions

Before starting Foracort, inform your healthcare provider if you have any of the following conditions, as they may affect whether and how you can use this medication:

• Active or quiescent pulmonary tuberculosis (TB): Inhaled corticosteroids may suppress local immune responses in the lungs. Patients with active TB require specific anti-tuberculous therapy and should not use inhaled corticosteroids until TB is adequately treated. Patients with quiescent TB should be monitored closely.
• Fungal, viral, or bacterial respiratory infections: Corticosteroids may mask or exacerbate respiratory infections. Existing infections should be adequately treated before initiating Foracort therapy.
• Cardiovascular disorders: Formoterol, as a beta-2 agonist, can produce cardiovascular effects including increased heart rate, elevated blood pressure, and cardiac arrhythmias. Patients with coronary artery disease, cardiac arrhythmias (particularly third-degree AV block), hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, or aneurysm should be monitored carefully.
• Diabetes mellitus: Beta-2 agonists may increase blood glucose levels. Patients with diabetes should monitor their blood sugar levels more closely when initiating or adjusting the dose of Foracort.
• Thyroid disorders (thyrotoxicosis): Beta-2 agonists may exacerbate the symptoms of hyperthyroidism.
• Hypokalemia: Beta-2 agonists may cause a decrease in serum potassium levels. This effect may be potentiated by concomitant use of xanthine derivatives, corticosteroids, or diuretics. Serum potassium levels should be monitored in patients at risk.
• Osteoporosis: Long-term use of inhaled corticosteroids, particularly at high doses, may reduce bone mineral density. Patients at risk for osteoporosis (post-menopausal women, elderly patients, patients on prolonged corticosteroid therapy) should be monitored and may benefit from bone-protective measures.
• Pheochromocytoma: Beta-2 agonists should be used with caution in patients with known or suspected pheochromocytoma.

Pregnancy and Breastfeeding

Foracort should be used during pregnancy only when the potential benefit to the mother outweighs the potential risk to the fetus. However, it is critical to understand that uncontrolled asthma during pregnancy poses significant risks to both mother and baby, including preeclampsia, gestational hypertension, intrauterine growth restriction, low birth weight, and preterm delivery. The risks of uncontrolled asthma generally outweigh the risks associated with the use of inhaled corticosteroids during pregnancy.

Of all inhaled corticosteroids, budesonide has the most extensive body of safety data in pregnancy. Large observational studies, including the Swedish Medical Birth Registry data involving over 6,000 pregnancies, have not demonstrated an increased risk of congenital malformations or other adverse pregnancy outcomes with inhaled budesonide use. GINA guidelines recommend that pregnant women with asthma should continue their controller medications, including inhaled corticosteroids, to maintain asthma control, as the risks of poorly controlled asthma to the fetus are greater than the potential risks of inhaled medications.

Limited data are available regarding the use of formoterol during pregnancy. Animal studies have shown adverse reproductive effects at very high systemic exposures (well above therapeutic doses), but there is no evidence of teratogenicity at clinically relevant doses. The decision to use formoterol during pregnancy should be made on an individual basis, weighing the benefit of optimal asthma control against any potential risk.

Budesonide is excreted in human breast milk in small amounts. At therapeutic inhaled doses, the amount reaching the infant via breast milk is expected to be negligible. Formoterol has been shown to be excreted in the milk of lactating rats, but it is not known whether it is excreted in human breast milk. Given the importance of breastfeeding and the low systemic absorption of inhaled budesonide/formoterol, the use of Foracort during breastfeeding is generally considered acceptable when the clinical benefit to the mother outweighs the potential risk to the infant. Discuss with your healthcare provider.

How Does Foracort Interact with Other Drugs?

Drug interactions with Foracort arise primarily from the pharmacological properties of its two active ingredients. Budesonide is metabolized principally by the cytochrome P450 enzyme CYP3A4 in the liver and intestinal wall, while formoterol exerts its effects through beta-2 adrenergic receptor activation. Both pathways can be influenced by concomitant medications, potentially altering the efficacy or safety profile of Foracort.

The following table summarizes the most clinically significant drug interactions with Foracort. Always inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements.

Major Interactions

Minor Interactions

Moderate CYP3A4 inhibitors, such as erythromycin and diltiazem, may modestly increase budesonide plasma levels but are generally not considered to produce clinically significant effects at standard inhaled doses. However, patients receiving multiple moderate CYP3A4 inhibitors concurrently should be monitored for signs of increased corticosteroid exposure.

Monoamine oxidase (MAO) inhibitors and tricyclic antidepressants may potentiate the cardiovascular effects of formoterol, including increased heart rate and blood pressure. Use Foracort with caution in patients receiving these medications, and avoid if possible within 14 days of discontinuing MAO inhibitor therapy.

There are no known significant interactions between Foracort and most commonly used asthma/COPD medications, including leukotriene receptor antagonists (montelukast), antimuscarinics (tiotropium, ipratropium), or short-acting beta-agonists used for rescue purposes.

What Is the Correct Dosage of Foracort?

Foracort dosage should always be individualized based on the severity of the disease, the patient’s current level of asthma or COPD control, and their response to treatment. The goal of therapy is to achieve and maintain disease control at the lowest effective dose. Once good control is achieved for an extended period, your doctor may consider a gradual dose reduction to find the minimum effective maintenance dose.

Adults (18 years and older)

Children and Adolescents (6–17 years)

Elderly Patients

No dose adjustment is required for elderly patients. Standard adult dosing recommendations apply. However, elderly patients may be more susceptible to certain side effects, including systemic corticosteroid effects on bone density and cardiovascular effects of formoterol. Regular monitoring of bone density and cardiovascular status is recommended in elderly patients receiving long-term treatment.

Missed Dose

If you forget to take a dose of Foracort, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and take your next dose at the usual time. Do not take a double dose to compensate for a missed one. Consistent adherence to the prescribed dosing schedule is important for optimal disease control. If you frequently forget doses, discuss strategies with your healthcare provider, such as setting reminders or simplifying your dosing regimen.

Overdose

An overdose of formoterol may cause tremor, headache, palpitations, tachycardia, hyperglycemia, hypokalemia, QTc prolongation, and in severe cases, ventricular arrhythmias. Nausea and vomiting may also occur. Treatment of acute formoterol overdose is generally supportive and symptomatic. Cardioselective beta-blockers may be considered with caution (as they may provoke bronchospasm) in severe cases with significant cardiac effects.

Acute overdose with budesonide, even in high doses, is not expected to present a clinically significant problem. Chronic overdose with inhaled budesonide may result in systemic corticosteroid effects, including adrenal suppression, growth retardation in children, decreased bone mineral density, cataract formation, and glaucoma. If long-term overdose is suspected, adrenal function should be assessed and the dose should be gradually reduced under medical supervision.

What Are the Side Effects of Foracort?

Like all medicines, Foracort can cause side effects, although not everyone will experience them. The side effects listed below are based on clinical trial data and post-marketing surveillance of budesonide/formoterol combination products. The frequencies are classified according to the following convention based on the Medical Dictionary for Regulatory Activities (MedDRA) system:

The local side effects of oral candidiasis and hoarseness are largely preventable by rinsing the mouth with water (and spitting it out) after each inhalation. Using a spacer device with a metered-dose inhaler can also help reduce oropharyngeal deposition and lower the risk of local side effects.

If you experience paradoxical bronchospasm (a sudden worsening of wheezing and shortness of breath immediately after using your inhaler), stop using Foracort, use your rescue inhaler, and seek immediate medical advice. This is a rare but potentially serious reaction that requires an alternative treatment strategy.

Long-term use of inhaled corticosteroids at high doses may be associated with systemic effects, although these are much less common and less severe than with oral corticosteroids. Monitoring for potential systemic effects, including regular assessment of adrenal function, bone density, and eye health, is recommended for patients receiving long-term high-dose inhaled corticosteroid therapy.

How Should You Store Foracort?

Proper storage of Foracort is essential to ensure the medication remains effective and safe to use throughout its shelf life. The following guidelines should be followed:

• Temperature: Store below 30°C (86°F). Do not expose the inhaler to temperatures above 50°C (122°F). Avoid storing near radiators, heating vents, or in direct sunlight.
• Freezing: Do not freeze the inhaler. The pressurised canister contains propellant that can be affected by extreme cold temperatures.
• Humidity: Keep the inhaler in a dry place. Avoid storing in bathrooms or other areas with high humidity.
• Canister care: The pressurised canister is under pressure. Do not puncture, break, or incinerate the canister, even when it appears to be empty. Do not expose it to open flames.
• Keep out of reach of children: Store the inhaler in a safe place where children cannot access it.
• Expiry date: Do not use Foracort after the expiry date printed on the packaging. The expiry date refers to the last day of the indicated month.
• After opening: Once the foil pouch is opened (if applicable), use the inhaler within the timeframe recommended in the patient information leaflet, typically within 3 months.

Do not dispose of medications via wastewater or household waste. Ask your pharmacist about appropriate disposal methods for medicines that are expired or no longer needed. Proper disposal helps to protect the environment.

What Does Foracort Contain?

Foracort is a pressurised inhalation suspension delivered via a metered-dose inhaler (MDI). Understanding its composition helps patients identify potential allergens and understand what they are inhaling with each dose.

Active Ingredients

• Budesonide 160 micrograms per actuation – an inhaled corticosteroid that reduces inflammation in the airways. Budesonide has a high ratio of local anti-inflammatory potency to systemic activity, making it well suited for inhaled delivery.
• Formoterol fumarate dihydrate 4.5 micrograms per actuation – a long-acting, selective beta-2 adrenergic agonist that provides rapid-onset (1–3 minutes) and long-duration (12+ hours) bronchodilation.

Inactive Ingredients (Excipients)

The formulation of Foracort pressurised inhalation suspension typically contains the following inactive ingredients:

• Norflurane (HFA-134a, 1,1,1,2-tetrafluoroethane): A hydrofluoroalkane propellant used to deliver the medication as a fine mist suitable for deep lung deposition. HFA propellants replaced chlorofluorocarbons (CFCs) in metered-dose inhalers due to environmental concerns regarding ozone depletion.
• Ethanol: Used as a co-solvent to maintain the uniform suspension of the active ingredients in the propellant.

Foracort is CFC-free. The HFA-134a propellant has no known effect on the ozone layer. Patients switching from CFC-containing inhalers to HFA-based inhalers may notice a slightly different taste or feel of the spray; this does not indicate a problem with the medication.

The inhaler device consists of a pressurised aluminium canister fitted with a metering valve, placed into a plastic actuator with a mouthpiece. The dose counter (if present) displays the number of actuations remaining. Patients should check the dose counter before each use and obtain a replacement inhaler when the counter indicates the prescribed number of doses has been delivered or when the spray becomes less forceful.